Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Debt / NOTE 0.250% 3/0
-
Market price (% of par)
-
88.39%
-
Total 13F principal
-
$712,881,662
-
Principal change
-
+$159,837,778
-
Total reported market value
-
$631,436,377
-
Number of holders
-
50
-
Value change
-
+$142,081,055
-
Number of buys
-
27
-
Number of sells
-
19
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q2 2022
As of 30 Jun 2022 HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 had 50 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $712,881,662 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included Allianz Asset Management GmbH, CAMDEN ASSET MANAGEMENT L P /CA, Davidson Kempner Capital Management LP, Invesco Ltd., CALAMOS ADVISORS LLC, AVIVA PLC, ADVENT CAPITAL MANAGEMENT /DE/, BlackRock Inc., CITIGROUP INC, and WOLVERINE ASSET MANAGEMENT LLC.
This table shows 50 bond principal holders of the security as of 30 Jun 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par) |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.